Buy these ASX growth shares now: analysts

Analysts reckon these growth shares have heaps of potential and should be in your portfolio…

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

If you're a growth investor on the lookout for new options, then read on!

Listed below are two ASX growth that could be worth considering . Here's why analysts are tipping them as buys:

A smiling man points upwards with both fingers in an exaggerated sideways pose.

Image source: Getty Images

Aristocrat Leisure Limited (ASX: ALL)

The first ASX growth share to consider buying is Aristocrat Leisure. It is one of the world's leading gaming technology companies with a world class portfolio of poker machines and mobile games.  The latter business, known as Pixel United, is home to popular mobile games such as Cashman Casino, Gummy Drop, EverMerge, Mech Arena, and RAID.

Aristocrat also recently expanded into the real money gaming market with a deal with MGM. This has the potential to be a very lucrative business in the future and is partly why Goldman Sachs is positive on the company. It commented:

Real Money Gaming opportunity was discussed to grow to penetrate at least 70% of the regulated jurisdictions in north America in the medium term. ALL will be targeting to take a significant share of the US iGaming market in the medium term with ambitions to be a leading global online RMG platform in the long term.

Goldman has a buy rating and $42.80 price target on its shares.

ResMed Inc. (ASX: RMD)

Another ASX growth share that has been tipped as a buy is ResMed. It is a medical device company with a focus on sleep treatment solutions.

Morgans rates the company highly due to its strong position in the sleep treatment market and its huge potential in the out of hospital care market. The broker commented:

Nothing changes our medium/longer term view that the company remains well-placed as it builds a unique, patient-centric, connected-care digital platform that addresses the main pinch points across the healthcare value chain.

Morgans has an add rating and $37.24 price target on its shares.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended ResMed. The Motley Fool Australia has positions in and has recommended ResMed. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Technology Shares

A female engineer inspects a printed circuit board for an artificial intelligence (AI) microchip company.
Technology Shares

Why it's time to look past the "SaaSpocolypse" and target Aussie tech

Here's why Aussies are pouring back into the tech sector.

Read more »

A financial expert or broker looks worried as he checks out a graph showing market volatility.
Technology Shares

I was going to buy these ASX tech stocks. Now, I'm not so sure

When the facts change, so should our buying...

Read more »

Two IT professionals walk along a wall of mainframes in a data centre discussing various things
Technology Shares

NextDC just raised $750 million, here's why the shares are climbing

The financial boost could spark the next phase of growth.

Read more »

A woman in a red dress holding up a red graph.
Technology Shares

This under the radar ASX tech company could deliver almost 50% returns: Broker

A strong growth forecast could underpin healthy returns.

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Technology Shares

Guess which ASX tech stock is rocketing 22% on big news

Let's see what is giving this tech stock a big lift on Friday.

Read more »

A smiling businessman sits at a desk with bags of money, indicating a share price rise after funding has been approved
Technology Shares

NEXTDC launches $750m wholesale notes to boost growth funding

NEXTDC lifts liquidity with $750m wholesale notes, supporting its capital plan and data centre growth ambitions.

Read more »

Military engineer works on drone.
Technology Shares

Up 209%, what's next for DroneShield shares?

Execution could drive long-term upside, but expect volatility ahead.

Read more »

Technology Shares

Why I'd invest $2,500 in Life360 and Pro Medicus shares today

Big share price declines don’t always mean broken businesses. Here’s why these shares stand out to me right now.

Read more »